Camras Vision has completed $5.7 million in Series A funding to support four clinical trials, including a U.S. pilot study to evaluate the efficacy of the Camras device for the treatment of refractory glaucoma, according to a press release.
The Camras device, which drains aqueous humor externally, is an investigational device not approved by the FDA.
The Series A equity funding was led by VCapital, InFocus Capital Partners and Triangle Venture Alliance.
“Our first-in-human trial overseas has been underway for the past 18 months and has shown encouraging preliminary results,” Camras
Uncategorized